DecodeME Study explained
Every day in clinics across Aotearoa, general practitioners are the first — and often only — clinicians to see the early signs of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). With recent Ministry of Health/Manatū Hauora and Open Medicine Foundation estimates suggesting that up to 185,000 New Zealanders may now be living with ME/CFS or Long COVID with ME‑like features, the scale of need is rapidly increasing. Most will present first to primary care. That places GPs in a uniquely powerful position: early recognition and early intervention can change the trajectory of this disease.
Why World ME Day Matters for Primary Care
World ME Day (12 May) highlights the importance of early recognition and harm‑prevention in general practice. ME/CFS is not rare, benign, or self‑limiting. It is a serious, multisystem neuroimmune disease that can lead to profound disability. Yet many patients remain undiagnosed for years — not because symptoms are invisible, but because they are misunderstood.
GPs can change that. Early recognition prevents harm, reduces deterioration, and helps patients stabilise before they fall into severe disease.
The DecodeME Study: What GPs Need to Know
DecodeME is the largest genetic study of ME/CFS ever conducted, analysing the DNA of 15,579 people with ME/CFS and 259,909 controls. DecodeME looked at genetic variants in DNA sequence — the fixed letters of the genome. These do not change because someone becomes ill. Chronic illness can change gene expression, but it cannot change gene sequence. The findings provide clear biological evidence of a multisystem disease involving immune signalling, neuroinflammation, mitochondrial function, and antiviral defence.
What DecodeME Found — in Plain Language
Researchers identified eight genomic regions where people with ME/CFS differ from those without the illness. These regions include genes involved in:
- Immune system regulation (SLC15A4, PRKCA, CD86, IL7R, HLA‑DQB1)
- Mitochondrial (cell powerhouse) dynamics and cellular energy regulation (AKAP1, ATP9A)
- Neuronal excitability and sensory processing (KCNB1)
In simple terms, these genes influence how the immune system switches on and off, how cells produce and manage energy, and how the nervous system processes signals.
DecodeME’s findings align with decades of biomedical research showing:
- Immune dysregulation
- Neuroinflammation
- Autonomic dysfunction
- Mitochondrial impairment
- Abnormal sensory processing
These results directly contradict outdated, flawed theories suggesting ME/CFS is caused by psychological factors, deconditioning, or maladaptive beliefs. The genetic signals identified in DecodeME are differences in DNA sequence — fixed from birth and not altered or caused by chronic illness, lifestyle, stress, or personality. This means the study isnot ‘capturing a symptom’; it is identifying biological predispositions (the underlying in-build tendencies in the body) that you are born with. These differences help explain why some people develop ME/CFS after a trigger such as a viral infection or other environmental stressor — their immune and neurological systems respond differently when challenged.
DecodeME reinforces what patients and clinicians have long observed: ME/CFS is a real, physical, biological disease.
The Cardinal Feature: Post‑Exertional Malaise
The most important diagnostic anchor remains Post‑Exertional Malaise (PEM) — the delayed, disproportionate worsening of symptoms after physical, cognitive, emotional, or orthostatic exertion.
If a patient does not have PEM, they do not have ME/CFS.
PEM is not “tiredness after activity”; it is a pathological crash that can last days or weeks. Patients often describe it as:
- “I can do things, but I pay for it later.”
- “I can’t bounce back.”
- “My body shuts down after I do things.”
Recognising PEM early allows GPs to guide patients toward safe activity management and avoid interventions that risk deterioration.
🚩Red Flags for GPs — When ME/CFS Should Be on Your Radar
GPs often see the earliest clues:
- A viral or infectious trigger followed by persistent decline
- Marked symptom worsening after even mild exertion
- Crashes occurring 12–48 hours after activity
- Cognitive overload or sensory intolerance
- Orthostatic symptoms such as dizziness or tachycardia
- Boom‑and‑bust cycling
- Failure to recover to baseline after exertion
These are the patients who need careful pacing guidance, harm‑prevention strategies, and monitoring for deterioration.
Why Early Intervention Matters
Early recognition allows GPs to:
- Prevent PEM episodes through pacing and activity stabilisation
- Avoid harmful graded exercise or “return to normal” plans
- Identify and manage orthostatic intolerance
- Document functional decline early for workplace/school support
- Prevent severity progression (mild ⇢ moderate ⇢ severe ⇢ very severe)
- Validate a very real and debilitating disease
The GP’s response in the first months of illness often determines whether a patient stabilises or deteriorates.
Where GPs Can Access the Full Clinical Toolkit
Visit the ANZMES World ME Day page for diagnostic criteria, PEM recognition tools, management principles, pacing guidance, and access to the World ME Alliance medical education hub.
The World ME Day Red Flags Guide focuses on early recognition and harm‑prevention.
The Know M.E. Clinical Education Programme (CME/CPD accredited) provides practical in‑clinic tools, early stabilisation strategies, and multimorbidity identification. GPs can begin immediately through the Micro‑Learning Series, delivered straight to their inbox.
Closing Message
With increasing prevalence ME/CFS is a major public health issue — and one that sits squarely in the domain of primary care. This World ME Day, ANZMES invites GPs to explore the red flags, deepen clinical understanding, and join the movement to #TakeMESeriously.
Access the GP Red Flags Guide and full clinical resources at:
https://anzmes.org.nz/world-me-day/take-me-seriously-2026/
